To uncover the mechanisms underlying the superior effect of the triplet vs anti-CD47/CD19 monotherapy, transcriptomic analyses were carried out on a set of six samples that included Raji mouse xenograft tumors (n=2) and CD20+ cells isolated from Raji, Daudi and two adult sporadic BL primary samples (one case with abdominal involvement and another case with bone marrow involvement), co-cultured with the bone marrow-derived stromal cell line, stromaNKtert (19), M2-polarized primary macrophages, primary circulating PBMCs, in the presence of either TG-1801 or TG-1801+U2 triplet. The gene discussed is CD19; the disease is Burkitt lymphoma.